Current treatments for IBD include inhibition of inflammation by corresponding drugs, because it has been demonstrated that pro-inflammatory cytokines and mediators play a crucial role in the pathogenesis of IBD and CAC, such as IL-1β, IL-6, TNF-α, iNOS and Cox-2 [4,21,28]. The gene discussed is NOS2; the disease is inflammatory bowel disease.